Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics

Early in its evolution, Enterococcus faecium acquired traits that allowed it to become a successful nosocomial pathogen. E. faecium inherent tenacity to build resistance to antibiotics and environmental stressors that allows the species to thrive in hospital environments. The continual wide use of antibiotics in medicine has been an important driver in the evolution of E. faecium becoming a highly proficient hospital pathogen. For successful prevention and reduction of nosocomial infections with vancomycin resistant E. faecium (VREfm), it is essential to focus on reducing VREfm carriage and spread. The aim of this review is to incorporate microbiological insights of E. faecium into practical infection control recommendations, to reduce the spread of hospital-acquired VREfm (carriage and infections). The spread of VREfm can be controlled by intensified cleaning procedures, antibiotic stewardship, rapid screening of VREfm carriage focused on high-risk populations, and identification of transmission routes through accurate detection and typing methods in outbreak situations. Further, for successful management of E. faecium, continual innovation in the fields of diagnostics, treatment, and eradication is necessary.


Introduction
Enterococci were first discovered in human fecal flora in 1899. However until 1984, they were still considered part of the genus Streptococci [1]. Streptococcus faecalis was first described in 1906 when the microorganism was isolated from a patient with endocarditis. Streptococcus faecium was first detected in 1919. Later on, streptococci belonging to serogroup D were divided into two groups. This division was made based upon studies demonstrating differences in biochemical and differences from nucleic acid (DNA-rRNA homology studies and 16SrRNA) [2]. Streptococcus faecalis and Streptococcus faecium were placed in the enterococcus group, which more than 50 species belong [3].
Among the enterococci, E. faecalis and E. faecium are the main causative agents of infection in humans. In the 1970s, enterococci emerged as a leading cause of hospital-acquired infections [4]. In the past two decades, E. faecium has rapidly evolved as a worldwide nosocomial pathogen by successfully adapting to conditions in a nosocomial setting and acquiring resistance against glycopeptides [5,6]. The resistance genes against glycopeptides are organized in van operons located on mobile genetic elements (MGEs). The operons include regulatory genes controlling the expression of ligase genes conferring resistance to glycopeptides, of which the vanA and vanB genes are the most common [7].
In this review, we will first describe the historical rise of E. faecium infections in hospitals worldwide, followed by the subsequent emergence and epidemiological background of vancomycin resistant E. faecium (VREfm). Next, we review difficulties in VRE detection and infection control in the modern hospital settings, in which E. faecium has emerged as an important pathogen in the past 20 years. Finally, we provide practical recommendations based on these microbiological insights.
The evolution of Enterococcus faecium as a hospitaladapted pathogen Population genetics and genomics showed that there are two distinct subpopulations of E. faecium. The first subpopulation represents commensals of the gastrointestinal (GI) tract and is usually not involved in clinical infection. The second subpopulation represents hospital-associated (HA) E. faecium lineages that cause nosocomial outbreaks and opportunistic infections in hospitalized patients. The presence of these distinct subpopulations were recognized two decades ago using amplified fragment length polymorphism (AFLP); a fingerprint-based typing method [8]. Later, sequence-based methods such as multi-locus sequence typing (MLST) and whole genome sequencing (WGS) confirmed and further described these distinct E. faecium subpopulations [9][10][11]. Currently, these two populations are designated as clade A and clade B. The successful HA lineages belong to a subclade of clade A, A1, previously designed as clonal complex 17 (CC-17) [12].
E. faecium isolates belonging to the HA subpopulation are characterized by ampicillin resistance and pathogenicity islands; they are also commonly associated with hospital outbreaks [11]. In addition, genome wide studies have shown that these HA isolates acquired a number of traits making them successful in the hospital environment; such as an increase in antibiotic resistance genes and virulence genes enhancing biofilm formation and colonization [13]. These adaptive traits are the result of gene acquisition and gene loss in E. faecium, which is facilitated by plasmid transfer, and through homologous recombination, mediated by insertion sequence (IS) elements. IS elements may provide homology at specific sites in the chromosome, allowing for integration of foreign genes by homologous recombination events [10]. The continuous refinement of genomic configuration, characterized by the flux and integration of successful adaptive traits, results in a selective advantage and clonal expansion of HA lineages [14] .
In the 2000's, nosocomial infections with ampicillin resistant E. faecium (AREfm) emerged in Europe, replacing E. faecalis infections [15]. In fact, European Antimicrobial Resistance Surveillance System (EARSS) data of 2002-2008 showed the largest increase (on average annually 19.3%) in the number of positive E. faecium blood cultures compared to the increase of other pathogens as E. coli, S. aureus, S. pneumoniae and E. faecalis [16]. This emergence of E. faecium bloodstream infections (BSI) was also observed in surveillance data of the University Medical Center Groningen (UMCG, The Netherlands). The ratio of positive blood cultures with E. faecium and E. faecalis in individual patients during 1998-2017 in shown in Fig. 1. While the incidence of E. faecalis BSI remained rather constant, the E. faecium to E. faecalis ratio changed approximately from 0.1 in 1998 to 1.6 in 2017. Hospitals in throughout Europe including Ireland, Spain, Poland, Denmark and Switzerland relate the increase of E. faecium bloodstream infections (BSI) to CC-17 clones [17][18][19][20][21]. Furthermore, countries outside Europe also observed increasing infections with E. faecium. The United States (US) observed an increase in E. faecium BSI from 2002, with a peak in 2010 (prevalence of 5.4%) [22]. An overview of antimicrobial-resistant pathogens causing hospital acquired infections in the US during 2011-2014, showed an overall contribution of E. faecium of 3.7% [23], with the highest contribution in catheterassociated urinary tract infections (CAUTI). In 2014, the Australian Enterococcal Sepsis Outcome Program (AESOP) reported that a large proportion (39.9%) of enterococcal bacteremia was caused by E. faecium [24].

Emergence and epidemiology of vancomycin resistant enterococci (VRE)
The acquisition of resistance against glycopeptides is an important landmark in the evolution of enterococci towards a highly resistant microorganism. The first reported (Van-A-type) VRE was in 1988 in France and the United Kingdom [25,26]. Most VRE outbreaks are due to HA-vancomycin susceptible E. faecium (VSEfm) that has acquired the vanA or vanB gene [27,28].
VanA-type VRE dominated the epidemiology of VRE in the US and Europe [29]. In the US, (vanA) VRE had already emerged by the 1990s while remaining rare in hospitals throughout Europe. In both continents, the emergence of AREfm preceded the emergence of VREfm [30]. In Europe, hospital infections with AREfm started to increase from 2000, followed by an increase in VREfm [31], which was comparable to the US 20 years earlier (Fig. 2).
In contrast to the US, Europe had a large reservoir of VRE in the community by the 1990s, yet without suitable HA AREfm populations in hospitals to take up the van genes and become HA VREfm. This large reservoir of VRE in the community and farm animals were linked to the avoparcin use in husbandry [28]. Avoparcin, a glycopeptide antibiotic similar to vancomycin, had been in use since 1970 as a growth promotor in the agricultural sector in several European countries. Its use was associated with high numbers of vanA-carrying VRE in meat products and samples from livestock [32,33]. Avoparcin was not used in the US and a community reservoir of VRE was therefore absent [34]. In the US, the rise in VRE was probably due to the extensive use of antibiotics in humans [35] along with failures in infection prevention measures leading to cross transmissions [36]. Because of the potential risk of transmission of VRE or van genes from the community into the hospitals, the use of avoparcin was banned in European countries in 1997. As a result, VRE in farm animals declined rapidly. However, persistence of vancomycin resistance in E. faecium in poultry farms has been reported in several European countries [37]. It is not known to which extent these mobile genetic elements (MGEs), such as (vanA) In Europe, this event started 20 years later. Note the different situation between the US and Europe; in contrast to the US, Europe did have a large reservoir of VRE in the community in the 1990s, yet without suitable HA AREfm populations in hospitals to take up the van genes and become HA VREfm. This reservoir of VRE was linked to the avoparcin use in husbandry. In blue: Hospital Clade A1-VSEfm (AREfm). In red: hospital-Clade A1 VREfm. HGT: horizontal gene transfer (of van genes). Threshold: hypothetical critical number of hospital clade A1 AREfm strains needed for the introduction of van genes transposons are still a potential reservoir for HA VREfm [38,39].
Data collected from 2011 to 2014 by the Centers for Disease Control and Prevention (CDC) about antibiotic resistant hospital acquired infections, showed a high but decreasing prevalence of VREfm in the US, from 80.5% in 2011 to 75.6% in 2014 [40,41]. Data from the European Center for Diseases and Control (ECDC) for 2016 showed variable surveillance data for VREfm between the European countries [42]. For example, the proportion of VREfm is < 1% in Sweden, Finland, the Netherlands and France; while Cyprus reports the highest proportion of 46.3% (Fig. 3). Notable increases in the proportion of VREfm has occurred in the following Eastern European countries: Romania, Latvia, Lithuania, Poland, Hungary, Slovakia, Croatia, Cyprus and Bulgaria (Fig. 4) Little is known which lineages and van-types are involved in the significant increase of VREfm in these countries.
Importantly, this increase in vanB VRE was reported in several European countries around 2005; amongst others in Spain, Greece, Germany and France [43]. A study from Poland investigated the VRE epidemiology from 1999 to 2010 and reported an increasing prevalence of vanB VREfm [44][45][46][47][48][49][50]. Hospitals in Sweden had a low prevalence of VRE, with vanB VRE being detected sporadically. In 2007, outbreaks in three Swedish hospitals occurred and further clonal dissemination from vanB VRE were seen [51]. In Germany, the emerge of vanB was typically associated with MLST ST192, a lineage within CC-17 [47,48]. In 2016, the proportion of vanB VRE was, for the first time, higher than vanA VRE [49]. .Also the Netherlands, reported a the quite significant proportion of vanB VRE. Of the 706 VRE strains that were analyzed between May 2012 and March 2016 from 42 Dutch hospitals, 363 carried the vanA gene, 340 the vanB gene, four carried both the vanA and vanB gene, and two carried the vanD gene [52].
Australia reports an increasing trend in VRE prevalence similar to many countries in Europe. The AESOP and AURA (Antimicrobial Use and Resistance in Australia) reports show a steady increase in VREfm from 36.5% in 2010, to 48.7% in 2015 [24,[53][54][55][56][57]. The latest AURA report of 2017 showed the percentage of VREfm in blood cultures of 2015 ranging from 11.3 to 75% in the different states and territories of Australia [56]. The majority of these isolates were grouped into CC-17. Since 2010 ST203 has had a predominant place across most regions of Australia. Other predominant sequence types are ST17, ST555 and the rapidly increasing ST796, largely replacing ST203 [54]. The emergence of this new clone demonstrates the flexibility of the E. faecium genome to continuously respond and adapt to hospital and Showing vancomycin resistance proportion rates in Enterococcus faecium in Europe for 2016. Dataset provided by ECDC based on data provided by World Health Organization (WHO) and Ministries of Health from the affected countries environmental changes. VanB-type VRE dominated the epidemiology of VRE in Australia, but in recent years VanA-type VRE has emerged. In 2010, vanA VREfm was rarely detected compared to 2014, when 18.5% of the VREfm bacteremia isolates harbored the vanA gene [58]. The recent emergence of vanA VREfm has been associated with several STs and vanA-containing plasmids. This suggests multiple introductions of the vanA operon into the circulating E. faecium clones. This could be due to sources in the community or through introduction by health-care associated travel from overseas [24].
Reports from countries in Asia, South-America, Africa, Russia and the Middle-East [59,60] about the emergence of VREfm demonstrate the successful spread HA-E. faecium lineages worldwide.
In summary, nosocomial VREfm lineages are on the rise in hospitals over all continents. Recent data showed the proportion E. faecium clinical isolates that are vancomycin resistant varies between < 1 and 46.3% in Europe, from 75 and 80% in the US, and from 11.3 and 75% in Australia. The incorporation of MGEs such as vanB-carrying transposons into successful circulating HA-VSEfm lineages is a significant factor in the emergence of vanB VREfm. This occurs via the exchange of large chromosomal fragments, including the transposon Tn1549 carrying the vanB resistance, between vanB VREfm and VSEfm [61][62][63][64][65][66]. Incidentally, de novo acquisition of Tn1549 from anaerobic gut microbiota to VSEfm may occur [49,67]. If these events are subsequently followed by clonal expansion, it could lead to an increase in numbers of vanB VREfm [68]. However, the success factors for the rapid dissemination of E. faecium are probably not limited to the acquisition of antibiotic resistance and virulence genes, but also to specific adaptations to hospital conditions. Difficulties to detect and control nosocomial VRE outbreaks E. faecium has to overcome many challenges to remain endemic in hospital environments. The spread of highly resistant microorganisms (HRMOs) in hospitals is generally limited by universal standard precautions and disinfection of patient rooms and medical equipment. In addition, the transmission can be stopped by contact isolation of patients and targeted antibiotic treatment for HRMOs. HRMOs that are undetectable may spread in the hospital and thereby have an advantage over detectable phenotypes. Diagnostic strategies may therefore have a selective role in the emergence of hospital lineages.
In literature, several evasion mechanisms has been reported in VanA-type as well as VanB-type VRE, avoiding detection by the standard recommended methods. The most common standard recommend methods used for detection of glycopeptide resistant enterococci are  [68,69].
Detection of vanB VRE can be challenging since routinely measured vancomycin MIC values can range from ≤0.5 mg/L to ≥32 mg/L, as has been shown when using the Vitek2 (bioMérieux) automatic susceptibility testing system [70]. Strains that are vanB positive but are determined to be vancomycin susceptible according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) susceptibility breakpoint of ≤4 mg/L [71,72], are at risk of spreading without detection. Percentages of these vanB-positive low-level vancomycin resistant VRE strains can range from 24.5-55% in hospital outbreak settings [73]. Moreover, the sensitivity of VRE screening declines as the fecal VRE density decreases and if the culture media is assessed at 24 h instead of 48 h [71,72]. This has led to the suggestion that multiple rectal swabs (up to four or five rectal swabs) are required to detect > 90-95% of the carriers [74]. The direct detection of vanB carriage by molecular detection can also be compromised by many false positive results due to vanB genes in non-enterococcal anaerobic bacteria present in the gut [75,76]. An enriched inoculated broth containing metronidazole can be used in a polymerase chain reaction (PCR)-based VRE screening. Additionally, cut-off cycle threshold (Ct)-values can be adjusted to differentiate between detection of van genes carried by VRE and interfering signals from the anaerobic flora [77][78][79][80][81].
VanA VRE detection can be complicated by variations in the phenotype. Van genes are located in an operon that include regulatory genes controlling their expression. The expression of resistance to the glycopeptide teicoplanin can be heterogeneous, corresponding into a VanB-phenotype [82]. The presence of vanS (sensor) and vanR (regulator) regulatory genes in the vanA cassette are essential for the expression of glycopeptide resistance. Some isolates can test vancomycin and teicoplanin susceptible because of major nucleotide deletions or even absence of vanS and vanR genes in the vanA transposon [83] or due to insertion of IS elements in the coding regions of the vanA transposon [84,85]. The vanA-positive enterococci that are phenotypically susceptible to vancomycin are also termed vancomycinvariable enterococci (VVE) [86]. The VVE are in 'stealth mode' and are at risk to spread without detection. In case of major deletions, or complete absence of vanS/R genes and thus being non-functional genes, strains will probably not revert under vancomycin therapy. However, in case of small deletions in the vanR/S region, or if the region is silenced by IS elements, VVE strains can revert into vancomycin resistant strains upon vancomycin therapy [87], which can lead to treatment failure.
VRE may also evade detection by molecular diagnostics because multiple distinct gene clusters may confer resistance to vancomycin. Nine different van ligase genes in enterococci have been described (vanA, B, C, D, E, G, L, M, and N) [86,88]. Since VRE outbreaks are mainly due to vanA and/or vanB VREfm [89][90][91][92], PCR-based methods most often only target vanA and vanB, but not the other types of van genes. VRE harboring mobile genetic islands with vanD are sporadically found in patients, but no dissemination of these islands has yet been detected [28,93]. However, its prevalence may be underreported since the vanD gene is not detected by routine molecular diagnostics.

Infection control measures
Enterococci are highly tenacious microorganisms by nature. Compared to their ancestors, enterococci acquired traits that have led to an increased tolerance to desiccation and starvation, which make them resistant to environmental stresses similar to modern hospitals [94]. To survive in a hospital environment the adaptive traits of high tenacity and resistance to disinfection procedures are important for the hospital VRE lineages, allowing them to survive for many years in a hospital environment [95]. Enterococci are therefore excellent indicators of environmental contamination [96,97]. Enterococci are often isolated from high-contact points such as bed rails, over-bed tables, blood-pressure cuffs, alarm buttons, toilet seats and door handles [98]. As a consequence, transmission of enterococci not only occurs directly through contaminated hands of health care workers, patients, or visitors, but also indirectly through contaminated environmental surfaces [99]. Contaminated surfaces represent hidden reservoirs, from which enterococci may re-emerge and colonize patients that are subsequently admitted to the contaminate room [7]. In attempts to eradicate persistent reservoirs with VRE, intensified cleaning measures like targeted cleaning of environmental surfaces using high concentrations of sodium chloride or decontamination with hydrogen peroxide vapor should be used [96,100].
Enterococci can be tolerant to low concentrations of chemicals such as alcohol and chlorine [101,102]. After the intensified introduction of alcohol-based hand rubs in Australian hospitals, the use of hand alcohols increased during 2001-2015. When investigating HA E. faecium strains isolated from Australian hospitals between 1998 and 2015, there was a significant increase in isopropanolol tolerance over time [103]. Although the alcohol tolerance experiments were established with a concentration of 23%, lower than the 70% which is used in hand alcohols, these tolerant E. faecium isolates still survived better than the less tolerant isolates after the 70% isopropanolol surface disinfection. This exemplifies how E. faecium can adapt to environmental changes such as an increased use of hand alcohols. Inter-individual differences in hand hygiene compliance between healthcare workers could lead to a variety in VREfm reductions on hands. In case of limited reduction, there might be an unforeseen spread of VREfm.
The characteristic of heat-resistance is an important adaptive trait of enterococci. In early studies, the exceptionality of heat-resistance in enterococci had been reported in investigating pasteurization of dairy products [104]. A study comparing heat resistance of VSE versus VRE showed that some vancomycin-resistant isolates even survived exposure to 80 degrees Celsius for several minutes [105]. This is of particular relevance for infection control practices, since disinfection procedures of bedpans regularly include heating at 80 degrees for 1 min.
Several infection prevention strategies have been advised by the CDC Hospital Infection Control Practices Advisory Committee (HICPAC) for controlling VRE such as; prudent use of vancomycin, education programs for hospital staff, early detection and reporting of VRE by clinical microbiology laboratories, and isolation precautions and implementation of infection-control measures to prevent transmission of VRE including contact isolation for VRE-positive patients [103]. It is difficult to state which infection prevention measure by itself has the highest impact. The implementation of hand hygiene and decreasing environmental contamination by cleaning measures have a significant impact on reducing the spread of VRE [106]. However, single infection prevention measures often fail to have a real effect on reducing VRE rates. A multifaceted program implementing several guidelines, such as advised by the HICPAC, are therefore often needed to observe a clear reduction in VRE rates [107,108].
Antibiotic use, especially metronidazole, vancomycin and cephalosporins are risk factors for VRE acquisition [109,110]. Treatment with antibiotics that have activity against anaerobic bacteria can lead to a profound proliferation of VRE in the GI tract and subsequent BSI [111][112][113][114]. Ceftriaxone usage has also been associated with VRE BSIs [111,115]. This demonstrates that the stringent use of antibiotics to reduce the selective pressure is important and has successfully been applied in controlling ongoing VRE outbreaks [116].
Since a patient with an infection caused by VRE could be the tip of an iceberg [117,118] active surveillance is needed to detect VRE-carriage in patients in high-risk units [119]. Screening patients transferred from foreign countries with high VRE prevalence is also another important infection prevention measure.

Molecular typing of VRE
In VRE outbreak investigations, rapid and accurate typing is required to investigate the genetic relatedness between patients' isolates. This information is essential to demonstrate nosocomial transmission and whether it is needed to enhance infection prevention measures. Rapid typing followed by infection prevention measures can lead to rapid control of nosocomial spread [75]. In Table 1, we summarized common used VRE typing methods and accompanying characteristics; reproducibility, ease of performance, data interpretation, ease of data exchange and costs.
WGS is increasingly used in (VRE) outbreak analysis [120] and provides the highest discriminatory power. In addition, WGS offers the possibilities to perform pangenome analysis to even enhance the assessment of genetic relatedness [48,121,122]. Additionally, a wide range of information can be extracted from WGS data such as MLST, core-genome (cg) MLST, whole-genome (wg) MLST data, virulence factors, resistance genes, plasmids and other genetic markers. However, there are some challenges to overcome to make it more accessible in daily routine clinical microbiology and outbreak analysis. Most important are the standardization and validation of procedures [123] and the interpretation of data [124]. The ease of data interpretation depends on the type of analysis to perform and which tools are available [125]. For example, cgMLST data can easily be extracted from WGS data by several in-house and commercially software packages. Compared to MLST, cgMLST has a higher discriminatory power in distinguishing genetically related and unrelated E. faecium isolates [126][127][128]. The advantage of cgMLST over single-nucleotide polymorphism (SNP)-based methods is that the data can easily be compared, stored and shared in web-based databases that can be interrogated (http://www.cgmlst.org/ncs/ schema/991893/). Importantly, if VRE outbreaks are caused by horizontal transfer of MGEs encoding vancomycin-resistance, studying the molecular epidemiology of these MGEs by specifically analyzing the various transposons encoding vanA or vanB gene clusters is essential. The use of WGS facilitates detailed analysis of variation in these transposons. These transposon analyses will enhance the resolution of used typing methods and provide better insight in VRE outbreaks [129].

Conclusion and future perspectives
In the future, it will be a challenge to withstand the spread of VREfm. A rapid and ongoing emergence of VREfm has been observed in countries in Central and Eastern Europe. Variances within same countries along with large regional differences have been observed in this rise of VREfm infections. This is underlined by the regional differences in VREfm proportions in German and Dutch regions. In 2016, the lowest proportion in Germany was reported in the region of North-West Germany (5.9%), which is in contrast with the  -Intensified cleaning procedures, including intensified cleaning procedures and prolonged disinfection procedures [132]. -Implementation of infection-control measures to prevent transmission of VRE, including isolation precautions for VRE-positive patients [97,101,103]. -Education programs for hospital staff, including hand hygiene to prevent further transmission [106]. -Environmental cultures in (uncontrolled) VRE outbreaks and surveillance cultures after disinfections.
Intrinsic resistance antibiotics -Outgrowth under antibiotic pressure.
-Prone to become pan-resistant.
Genome plasticity -Continuously adaptation and refinement in response to environmental changes. -Development of resistance to newer antibiotics and disinfectants in the future.
-Continuous awareness and surveillance to detect resistance to newer antibiotics and disinfectants. -Further research and development of antimicrobial targets for the treatment of MDR E. faecium [106].   [131]. VRE infections are commonly preceded by VRE-carriage, as described in our review. Early detection of carriage may prevent the spread and reduce the number infections. In the Netherlands there have been many outbreaks with patients carrying VRE. These outbreaks were controlled in an early phase, and thereby the proportion of infections with VRE is still low in the Netherlands. Thus, if the goal of a hospital is to prevent VREfm infections, special attention is required to reduce the VREfm spread by screening for VREfm-carriage. Other important factors are the role of hospital environment contamination by VREfm and the challenges in detection and typing of VREfm. We summarize recommendations described in literature and/or by guidelines in Table 2. Many of the recommendations follow directly from the microbiological traits of E. faecium as we reviewed. So far, these recommendations have shown to be successful in the control of VREfm in the Netherlands. However, these measures are very expensive and require a lot of effort from medical (molecular) microbiologists and infection control specialists [106]. Adequate VREfm diagnostics and typing can be difficult, as described in this review. Innovations in the detection and typing of VREfm are required to overcome these difficulties. Development of better selective media, PCRs with higher specificity, or rapid point of care tests are needed to detect VREfm more efficiently. A promising development is the use of clone-specific PCRs, which might be helpful to detect and control VREfm outbreaks caused by specific clones [118]. This method combines typing and detection in a rapid and cost-effective manner [138].
It is a point of debate whether these efforts are worthwhile to control the spread of VREfm. The attributable mortality of the currently successful VREfm lineages is mainly due to inappropriate (empirical) antibiotics rather than additional virulence of vancomycin resistance [139]. However, treatment options are limited in VREfm, since E. faecium is intrinsically resistant to many antibiotic classes. Resistance to several last-line enterococcal drugs like linezolid, daptomycin, tigecycline, and quinopristindalfopristin have already emerged [140][141][142]. Further research and development of antimicrobial targets is needed for the treatment of multidrug resistant (MDR) E. faecium [143][144][145][146]. Development of new antibiotics is expensive, requires time, and has a risk of rapid development of resistance to these new drugs. Therefore, it is important to use the current available antibiotics prudently and optimize adherence to hygiene precautions to prevent the patient-to-patient spread of VREfm resistant to these lastline antibiotics. It may be wise to reduce the spread of VREfm by surveillance in high risk populations. However, in many hospitals this might be difficult to realize. Capacity building programs and structural financial support for hospitals would be needed to implement efficient nosocomial screening for VREfm-carriage and subsequent infection control measures. Cross-border collaborations may prove useful in the implementation of such programs and have previously shown to be successful in decreasing the methicillin resistant Staphylococcus aureus (MRSA) prevalence in the Dutch-German Euregion [135].